Understanding Multiplex Immunofluorescence: Choosing the Right Technology for Discovery, Biomarker Development, and Clinical Research

Not all multiplex immunofluorescence technologies are designed for the same objective. This guide compares the main categories and explains which workflows are best for discovery, biomarker development, and clinical research.

by Jeff Chamberlain, PhD · Director, Biopharma Partnerships · RareCyte

As spatial proteomics adoption accelerates across translational and clinical research, researchers are faced with an increasingly complex landscape of multiplex immunofluorescence technologies.

Each approach offers different strengths, tradeoffs, and workflow characteristics. Some technologies prioritize maximum biological exploration. Others emphasize throughput, reproducibility, and operational scalability.

Importantly, there is no universal “best” platform. The right technology often depends on the scientific and operational goals of the study.

Researchers focused on early-stage discovery may prioritize ultra-high plex analysis and exploratory flexibility. Translational and clinical research programs, however, require workflows capable of supporting larger cohorts, standardized assays, and reproducible deployment across sites and studies.

Between early discovery and clinical testing sits biomarker development — a critical stage where researchers must translate broad biological insight into focused, clinically actionable biomarker strategies.

Understanding these distinctions is becoming increasingly important as spatial biology moves from exploratory science toward clinical implementation.

The case for multiplex immunofluorescence

Traditional IHC and low-plex immunofluorescence workflows remain widely used in both research and clinical pathology environments. These approaches are well established, operationally familiar, and relatively easy to standardize. They are often highly effective when researchers need to evaluate a limited number of well-characterized biomarkers.

However, low-plex workflows become limiting when studying complex tissue biology or heterogeneous immune environments. Increasing the number of biomarkers analyzed with these methods requires imaging on adjacent tissue sections, but this loses spatial context and highlights the very practical challenge of using more of the precious tissue samples.

As translational research increasingly requires multidimensional tissue characterization, many organizations are adopting multiplex immunofluorescence workflows capable of generating richer biological insight. Multiplex immunofluorescence (mIF) detects multiple targets on a single tissue section, measuring several biomarkers simultaneously while preserving tissue architecture.

Why multiplex depth matters

The biological questions being asked in translational research have evolved significantly over the past decade.

Historically, tissue analysis often focused on determining whether a single biomarker was present or absent. Today, researchers increasingly need to understand the composition, functional state, and spatial organization of entire cellular ecosystems within the tumor microenvironment.

For example, identifying a cytotoxic T cell population may require only a few markers. Determining whether those same cells are activated, exhausted, proliferating, excluded from the tumor, or actively engaging tumor cells requires substantially more biological context.

Researchers increasingly need to evaluate:

• Cell identity markers
• Functional state markers
• Activation and exhaustion markers
• Tumor biomarkers
• Stromal biomarkers
• Spatial relationships between cell populations

As a result, many biomarker development programs require more than 6 biomarkers to adequately characterize the biology associated with therapeutic response or resistance.

Importantly, the goal is not to measure as many proteins as possible. The goal is to generate sufficient biological context to identify the biomarkers most likely to influence clinical outcomes.

This distinction is important because it shifts the conversation from:

"How many markers can a platform measure?"

to:

"Can the platform generate enough biological insight to identify and validate meaningful biomarker signatures?"

With that context established, researchers can more effectively evaluate the strengths and limitations of the major multiplex immunofluorescence technologies available today.

The major categories of multiplex immunofluorescence technologies

Most multiplex immunofluorescence approaches used in translational and clinical research today fall into three broad categories:

• Signal amplification-based multiplex imaging
• Cyclic immunofluorescence imaging
• Single-round high-plex imaging

Each approach offers different strengths, tradeoffs, and workflow characteristics.

Signal amplification-based approaches build upon traditional fluorescence imaging by using sequential staining workflows combined with amplification chemistries to increase multiplexing capability and improve detection sensitivity.

These workflows have played an important role in expanding multiplex tissue analysis within translational research.

Compared with low-plex approaches, amplification-based methods can provide:

• Moderate multiplex capability, ~6 biomarkers
• Improved signal sensitivity
• Better characterization of spatial relationships

At the same time, the sequential staining process often adds complexity to panel design due to the umbrella effect and changes to the antigen binding epitopes through reagent cycling.

The umbrella effect refers to the amplification chemistry for one biomarker creating a steric hindrance and/or masking of signal of other biomarkers.

Similarly, antigen binding epitopes are labile to repeated exposure to amplification reagents (some more than others), such that the order of biomarker amplification must be experimentally optimized.

Both of these factors can confound the biological accuracy of the assay. Cyclic staining is also long, complex, requires an autostainer, and can result in tissue integrity issues.

hese approaches can be well suited for translational research environments requiring moderate multiplex depth for high-volume studies; however, the practical multiplex limit may constrain the ability to simultaneously characterize cell identity, functional state, and spatial relationships across complex tissue microenvironments.

Cyclic imaging workflows use repeated cycles of staining, imaging, and signal removal to measure large numbers of biomarkers within the same tissue section.

These methods are often used in exploratory research environments because they can achieve very high plex levels and enable detailed characterization of complex cellular states. For discovery-focused researchers, this level of biological depth can be extremely valuable, especially for hypothesis generation.

Despite their ability to achieve very high plex levels, cyclic workflows introduce several operational considerations that become increasingly important in larger translational and clinical research studies:

• Low sample capacity – Because staining and imaging must occur sequentially across multiple cycles, overall workflow duration increases as plex grows. This limits the number of samples that can be processed within a given timeframe and can create challenges when scaling studies to larger cohorts or processing multiple experiments at the same time.
• Increased risk to sample integrity – With progressive rounds of staining and imaging, tissue can move, fold, or detach from the slide.
• Variable antigenicity – Antigen binding epitopes can change from round to round from repeated exposure to the staining and removal reagents, potentially resulting in a variable fluorescent signal intensity and assay performance.

As studies scale into larger cohorts or multi-site programs, throughput and standardization can become more challenging.

For many organizations, these technologies are best suited for discovery-oriented applications where maximum biological exploration is the primary objective.

Single-round high-plex imaging workflows are designed to capture larger multiplex panels within a single staining and imaging process.

Unlike cyclic workflows, these approaches combine higher plex capability with simplified operational workflows, improved tissue and antigen preservation, and greater scalability.

This distinction becomes increasingly important in biomarker development and clinical trial environments.

Biomarker development occupies a critical phase between early discovery research and clinical trial deployment. This stage often requires multiplex panels in the 10-20 biomarker range, where researchers can simultaneously characterize cellular identity, functional state, and spatial relationships while still maintaining assay reproducibility and operational scalability.

Importantly, the goal during biomarker development is not necessarily to measure the largest number of proteins possible. Instead, researchers must confidently narrow complex biology into a smaller set of clinically actionable biomarkers capable of supporting translational decision-making.

This process requires workflows that balance biological depth with data quality, operational reproducibility, and scalability.

Single-round high-plex imaging approaches are increasingly being adopted in these environments because they help bridge the gap between exploratory biology and clinically scalable tissue analysis.

Compared with highly iterative workflows, these systems offer:

• Improved data quality
• Simplified workflows
• Higher throughput
• Better scalability for larger cohorts
• More reproducible assay deployment
• Reliable panel development

These same advantages are especially valuable in clinical trials.

In clinical trial biomarker programs, the priority shifts from maximum biological exploration to reproducible, scalable, and operationally robust assays that can:

• Support large patient cohorts across multiple sites
• Deliver consistent results across runs, instruments, and centers
• Fit within clinical timelines and operational constraints
• Provide high-quality spatial data that can inform patient stratification, response assessment, and mechanistic understanding
• Serve as a foundation for companion diagnostic development and regulatory discussions

For biomarker validation, patient stratification, and clinical trial workflows, reproducibility and scalability requirements are balanced with sufficient biomarker depth to resolve tissue microenvironments.

Single-round high-plex imaging represents a fundamentally different approach for spatial proteomics. By capturing high-plex biomarker panels in a single staining and imaging workflow, these systems are designed to combine biological depth with the reproducibility, throughput, and scalability required for translational and clinical research.

Today, Orion™ is the leading platform built on this architecture, enabling researchers to image across 20 channels simultaneously on a single tissue section while preserving tissue integrity and supporting clinical-scale workflows.

Discovery research and clinical research require different workflows

One of the biggest misconceptions in spatial biology is that the highest-plex technology is automatically the best technology. In reality, the optimal workflow depends heavily on the intended application. Discovery research and clinical research often prioritize very different outcomes.

Discovery-focused priorities

Discovery environments often emphasize:

• Maximum biomarker depth
• Experimental flexibility
• Exploratory biology
• Rare cell characterization
• Hypothesis generation

In these settings, because the primary goal is maximizing biological exploration, researchers may accept:

• Lower throughput
• Greater workflow complexity
• Longer turnaround times
• More intensive computational analysis

Clinical and translational priorities

Translational and clinical research environments typically prioritize:

• Reproducibility
• Assay robustness
• Throughput
• Workflow standardization
• Tissue preservation
• Multi-site consistency
• Scalable deployment

Operational performance becomes increasingly important.

The limiting factor is often not multiplex depth alone, but whether the workflow can reliably support larger studies, standardized assays, and clinically relevant timelines. Platforms that provide these capabilities will enable the transition in clinical testing from single- and low-plex methods (e.g., IHC) to more informative and actionable biomarker readouts.

In a recent webinar hosted by Fierce Pharma featuring Navigate Biopharma Solutions, the speakers discussed the growing importance of scalable and reproducible spatial biology workflows in clinical research environments. The conversation reflected a broader shift occurring across the field: as spatial proteomics moves closer to clinical implementation, operational scalability becomes increasingly critical. Watch the webinar on-demand →